Regeneron (REGN) Tops Q4 EPS by 58c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
February 6, 2020 6:30 AM ESTTARRYTOWN, N.Y., Feb. 6, 2020 /PRNewswire/ --
Fourth quarter 2019 revenues increased 13% to $2.17 billion versus fourth quarter 2018 Fourth quarter EYLEA® U.S. net sales increased 13% to $1.22 billion versus fourth quarter 2018 and full year 2019 EYLEA U.S. net sales increased 14% versus 2018 Dupixent® global net sales(2), which are recorded by Sanofi, increased 136% to $752 million versus fourth quarter 2018 and increased to $2.32 billion for full year 2019 Fourth quarter 2019 GAAP diluted EPS was $6.93 and fourth quarter non-GAAP diluted EPS(1) was $7.50 The Company and Sanofi announced intent to restructure... More